Impact of Multi-Drug Sequential Therapy on Survival in Patients with Unresectable Hepatocellular Carcinoma.
作者信息
Kudo Masatoshi
机构信息
Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
出版信息
Liver Cancer. 2021 Feb;10(1):1-9. doi: 10.1159/000514194. Epub 2021 Jan 28.
Abstract
摘要
相似文献
1
Impact of Multi-Drug Sequential Therapy on Survival in Patients with Unresectable Hepatocellular Carcinoma.多药序贯疗法对不可切除肝细胞癌患者生存的影响
Liver Cancer. 2021 Feb;10(1):1-9. doi: 10.1159/000514194. Epub 2021 Jan 28.
2
Safety and efficacy of sorafenib followed by regorafenib or lenvatinib in patients with hepatocellular carcinoma.索拉非尼序贯瑞戈非尼或乐伐替尼治疗肝细胞癌患者的安全性和疗效
Hepatol Res. 2021 Feb;51(2):190-200. doi: 10.1111/hepr.13588. Epub 2020 Dec 4.
3
Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan.序贯索拉非尼和瑞戈非尼治疗晚期肝细胞癌：日本多中心回顾性研究。
Invest New Drugs. 2020 Feb;38(1):172-180. doi: 10.1007/s10637-019-00801-8. Epub 2019 Jun 6.
4
Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families.分子靶向抗癌药物通过调节 MMP 和 TIMP 基因家族的表达抑制肝癌的侵袭和转移。
Biochem Biophys Res Commun. 2018 Oct 12;504(4):878-884. doi: 10.1016/j.bbrc.2018.08.203. Epub 2018 Sep 12.
5
Interstitial pneumonia suspected during regorafenib administration and exacerbated by subsequent therapy with lenvatinib for unresectable hepatocellular carcinoma.在瑞戈非尼治疗期间怀疑发生间质性肺炎，并因随后使用乐伐替尼治疗不可切除肝细胞癌而加重。
Clin J Gastroenterol. 2019 Aug;12(4):355-360. doi: 10.1007/s12328-019-00983-x. Epub 2019 Apr 24.
6
CRISPR/Cas9 genome-wide screening identifies KEAP1 as a sorafenib, lenvatinib, and regorafenib sensitivity gene in hepatocellular carcinoma.CRISPR/Cas9全基因组筛选确定KEAP1为肝细胞癌中索拉非尼、乐伐替尼和瑞戈非尼的敏感性基因。
Oncotarget. 2019 Dec 17;10(66):7058-7070. doi: 10.18632/oncotarget.27361.
7
Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies.晚期不可切除肝细胞癌患者的系统治疗：治疗方法的出现
J Gastrointest Cancer. 2018 Jun;49(2):107-115. doi: 10.1007/s12029-018-0065-8.
8
A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC.乐伐替尼与索拉非尼作为不可切除肝细胞癌经动脉治疗挽救疗法的真实世界比较分析
J Clin Med. 2020 Dec 21;9(12):4121. doi: 10.3390/jcm9124121.
9
Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.序贯治疗中包括仑伐替尼治疗不可切除肝细胞癌的重要临床因素。
Oncology. 2019;97(5):277-285. doi: 10.1159/000501281. Epub 2019 Jul 15.
10
Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma-Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice.索拉非尼-瑞戈非尼序贯疗法用于日本不可切除肝细胞癌患者——现实世界实践中的相对剂量强度及瑞戈非尼治疗后情况
Cancers (Basel). 2019 Oct 9;11(10):1517. doi: 10.3390/cancers11101517.
引用本文的文献
1
The Immune Inductive Role of Hepatic Arterial Infusion Chemotherapy Prior to Atezolizumab Plus Bevacizumab Combination Therapy in Hepatocellular Carcinoma.在肝细胞癌中，阿替利珠单抗联合贝伐单抗治疗前肝动脉灌注化疗的免疫诱导作用。
Gastro Hep Adv. 2024 Feb 1;3(4):506-509. doi: 10.1016/j.gastha.2024.01.013. eCollection 2024.
2
The Impact of Sequential Therapies after First-Line Systemic Therapies in Unresectable Hepatocellular Carcinoma.一线全身治疗后序贯治疗对不可切除肝细胞癌的影响
J Clin Med. 2024 Apr 29;13(9):2612. doi: 10.3390/jcm13092612.
3
Efficiency and safety of hepatic arterial infusion chemotherapy (HAIC) combined with anti-PD1 therapy versus HAIC monotherapy for advanced hepatocellular carcinoma: A multicenter propensity score matching analysis.肝动脉灌注化疗（HAIC）联合抗 PD-1 治疗与 HAIC 单药治疗晚期肝细胞癌的疗效和安全性：一项多中心倾向评分匹配分析。
Cancer Med. 2024 Jan;13(1):e6836. doi: 10.1002/cam4.6836. Epub 2024 Jan 9.
4
Complications of immunotherapy in advanced hepatocellular carcinoma.晚期肝细胞癌免疫治疗的并发症
J Liver Cancer. 2024 Mar;24(1):9-16. doi: 10.17998/jlc.2023.11.21. Epub 2023 Nov 29.
5
The impact of curative conversion therapy aimed at a cancer-free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.阿替利珠单抗联合贝伐珠单抗治疗肝细胞癌患者的无癌状态为目标的治愈性转换治疗的影响。
Cancer Med. 2023 Jun;12(11):12325-12335. doi: 10.1002/cam4.5931. Epub 2023 Apr 16.
6
Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non-viral infection: A Japanese multicenter observational study.阿替利珠单抗与贝伐珠单抗治疗乙型和非乙型肝炎病毒感染的肝细胞癌患者的疗效和安全性比较：一项日本多中心观察性研究。
Cancer Med. 2023 Mar;12(5):5293-5303. doi: 10.1002/cam4.5337. Epub 2022 Oct 13.
7
The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC-GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis.肝细胞癌改良 Gustave Roussy 免疫评分（HCC-GRIm 评分）作为阿替利珠单抗和贝伐珠单抗治疗患者的新型预后评分：一项多中心回顾性分析。
Cancer Med. 2023 Feb;12(4):4259-4269. doi: 10.1002/cam4.5294. Epub 2022 Sep 26.
8
Case Report: Exacerbation of varices following atezolizumab plus bevacizumab treatment of hepatocellular carcinoma: A case series and literature review.病例报告：阿替利珠单抗联合贝伐单抗治疗肝细胞癌后静脉曲张加重：病例系列及文献综述
Front Oncol. 2022 Jul 22;12:948293. doi: 10.3389/fonc.2022.948293. eCollection 2022.
9
Determinants of Survival and Post-Progression Outcomes by Sorafenib-Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma.索拉非尼-瑞戈非尼序贯治疗不可切除肝细胞癌的生存及进展后结局的决定因素
Cancers (Basel). 2022 Apr 15;14(8):2014. doi: 10.3390/cancers14082014.
10
Sorafenib Versus Lenvatinib-Based Sequential Systemic Therapy for Advanced Hepatocellular Carcinoma: A Real-World Analysis.索拉非尼与仑伐替尼序贯全身治疗晚期肝细胞癌：一项真实世界分析
Cancers (Basel). 2022 Apr 13;14(8):1975. doi: 10.3390/cancers14081975.
本文引用的文献
1
Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD-1/PD-L1 Checkpoint Blockade.对于先前接受PD-1/PD-L1检查点阻断治疗失败的不可切除肝细胞癌患者，乐伐替尼治疗的探索性分析
Cancers (Basel). 2020 Oct 20;12(10):3048. doi: 10.3390/cancers12103048.
2
A Paradigm Change in the Treatment Strategy for Hepatocellular Carcinoma.肝细胞癌治疗策略的范式转变
Liver Cancer. 2020 Aug;9(4):367-377. doi: 10.1159/000507934. Epub 2020 Jun 29.
3
Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma.肿瘤成纤维细胞生长因子受体4水平可预测晚期肝细胞癌患者使用乐伐替尼的疗效。
Clin Transl Gastroenterol. 2020 May;11(5):e00179. doi: 10.14309/ctg.0000000000000179.
4
Pathological Complete Response in Conversion Hepatectomy Induced by Lenvatinib for Advanced Hepatocellular Carcinoma.乐伐替尼诱导晚期肝细胞癌转化性肝切除术后的病理完全缓解
Liver Cancer. 2020 Jun;9(3):358-360. doi: 10.1159/000506202. Epub 2020 Mar 5.
5
A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements.中期肝细胞癌治疗模式的转变：亚太地区原发性肝癌专家共识声明
Liver Cancer. 2020 Jun;9(3):245-260. doi: 10.1159/000507370. Epub 2020 May 13.
6
Sequential systemic treatment in patients with hepatocellular carcinoma.序贯系统治疗肝细胞癌患者。
Aliment Pharmacol Ther. 2020 Jul;52(1):205-212. doi: 10.1111/apt.15789. Epub 2020 May 20.
7
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
8
Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma.一线使用乐伐替尼后序贯全身抗癌药物的疗效：来自不可切除肝细胞癌3期REFLECT研究的事后应答者分析
Liver Cancer. 2020 Jan;9(1):93-104. doi: 10.1159/000504624. Epub 2019 Dec 16.
9
Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib.接受乐伐替尼治疗的不可切除肝细胞癌患者进展后治疗的资格
Liver Cancer. 2020 Jan;9(1):73-83. doi: 10.1159/000503031. Epub 2019 Oct 18.
10
Sorafenib: Experience and Better Manage-ment of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis.索拉非尼：副作用的处理经验及优化管理可改善肝细胞癌患者的总生存期：一项真实世界回顾性分析
Liver Cancer. 2019 Nov;8(6):457-467. doi: 10.1159/000497161. Epub 2019 Mar 27.
Zotero 插件